| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 50.21 | 6.0% | 11.4% |
| Total Income | 50.21 | 6.0% | 11.4% |
| Expenditure | 65.89 | 2.4% | 9.4% |
| PBT | — | ||
| Net Profit | -16.29 | 6.4% | 6.0% |
| OPM | -31.22% | 4.60pp | 2.35pp |
| NPM | -32.44% | 4.28pp | 1.63pp |
| EPS | -0.26 | 7.1% | 4.0% |
Treace Medical Concepts Reports Q3 2025 Revenue Up 11% YoY
04 May 2026 · 4 May, 7:51 am
Summary
Treace Medical Concepts reported revenue of $50.2 million for the third quarter of 2025, an 11% increase compared to $45.1 million in the third quarter of 2024. The company's net loss for the quarter was $(16.3) million, and adjusted EBITDA loss improved by 49% to $(2.6) million. The company has revised its full-year 2025 revenue guidance to $211 million to $213 million, representing growth of 1% to 2% compared to full-year 2024. Management noted that revenue growth reflects greater market penetration, but Lapiplasty volumes have been impacted by a shift towards minimally invasive solutions and macroeconomic conditions.
Key Highlights
- 1
Treace Medical Concepts generated revenue of $50.2 million in the third quarter of 2025, representing an 11% increase compared to the same period in 2024.
- 2
The company reported a third quarter 2025 net loss of $(16.3) million.
- 3
Adjusted EBITDA improved by 49% to $(2.6) million in the third quarter of 2025, compared to $(5.1) million in the same period in 2024.
- 4
The company expanded its bunion technology portfolio in the third quarter with the full market release of the Nanoplasty® and Percuplasty™ 3D MIS Osteotomy Systems, and the SpeedMTP® MTP Fusion System.
- 5
Treace broadened its global patent portfolio, which now totals 122 granted patents in addition to 194 pending patent applications.
- 6
The company is revising its full-year 2025 revenue guidance to $211 million to $213 million, representing growth of 1% to 2% compared to full-year 2024.
Management Comments
John T. Treace
Our revenue growth in the third quarter reflects greater market penetration with our expanded portfolio of solutions, along with higher than planned sales to a limited number of stocking distributors that we do not expect to recur at the same level. At the same time, Lapiplasty volumes have been impacted as surgeons and patient preferences shift towards minimally invasive solutions, and we are seeing broader macroeconomic conditions and softer consumer sentiment resulting in a greater number of deferrals of elective bunion procedures. These headwinds have continued early into the fourth quarter, and as a result, we are revising our outlook for the full year. Looking ahead, while we have lowered our growth expectations for 2025, we remain the leader in the bunion market, and we believe we are in a stronger position to drive market share gains with our new products, innovation pipeline and ability to leverage investments in our commercial organization. Our team is focused on increasing our topline growth, improving profitability and delivering value to our shareholders.”
Informational and educational content only. Not investment advice.